X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
Details:
Lexicon lead product Inpefa (sotagliflozin), SGLT2/SGLT1 inhibitor. Currently, it is being evaluated in the Phase III clinical trial studies with patients for the treatment of Diabetes Mellitus Type 1 and chronic kidney failure.
Lead Product(s): Sotagliflozin
Therapeutic Area: Endocrinology Product Name: Inpefa
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 12, 2024
Details:
Inpefa (sotagliflozin) is a small molecule dual inhibitor of SGLT1 and SGLT2, which is being evaluated for the treatment of type 1 diabetes and chronic kidney disease.
Lead Product(s): Sotagliflozin
Therapeutic Area: Endocrinology Product Name: Inpefa
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2024
Details:
INPEFA (sotagliflozin) is an oral Tablet inhibitor of two proteins responsible for glucose regulation known as SGLT2 and SGLT1 and reduce the risk of cardiovascular death, hospitalization for heart failure.
Lead Product(s): Sotagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Inpefa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2023
Details:
Lexicon intends to use the proceeds from the public offering to fund the commercial launch of FDA approved, Inpefa (sotagliflozin), an orally-delivered small molecule, a sodium-glucose cotransporter type 2 inhibitor that also inhibits SGLT1, for the treatment of heart failure.
Lead Product(s): Sotagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Inpefa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Citigroup
Deal Size: $71.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 05, 2023
Details:
Lexicon intends to use the proceeds to fund the commercial launch of Inpefa (sotagliflozin), an inhibitor of SGLT2 and SGLT1 approved for the treatment of heart failure, and to fund the continued research and development of its drug candidates.
Lead Product(s): Sotagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Inpefa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Citigroup
Deal Size: $62.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 01, 2023
Details:
Lexicon currently intends to use the net proceeds to fund the commercial launch of Inpefa (sotagliflozin), an inhibitor of SGLT2 and SGLT1, recently approved by FDA for the treatment of heart failure.
Lead Product(s): Sotagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Inpefa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Citigroup
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering May 31, 2023
Details:
INPEFA™ (sotagliflozin) is an oral Tablet inhibitor of two proteins responsible for glucose regulation known as SGLT2 and SGLT1 and reduce the risk of cardiovascular death, hospitalization for heart failure.
Lead Product(s): Sotagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Inpefa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2023
Details:
SAR439954 (sotagliflozin) is an oral dual inhibitor of two proteins responsible for glucose regulation known as SGLT1 and SGLT2. SGLT1 is responsible for glucose absorption in the gastrointestinal tract, and SGLT2 is responsible for glucose reabsorption by the kidney.
Lead Product(s): Sotagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: SAR439954
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2023
Details:
Treatment with sotagliflozin (SAR439954) demonstrated significant relative risk reductions for non-fatal heart failure events and for the composite of cardiovascular death and readmission for heart failure at 30 or 90 days following hospital discharge versus placebo.
Lead Product(s): Sotagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: SAR439954
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2022
Details:
SAR439954 (sotagliflozin) is an investigational oral dual inhibitor of two proteins responsible for glucose regulation known as SGLT1 and SGLT2. SGLT1 is responsible for glucose absorption in the GI tract, and SGLT2 is responsible for glucose reabsorption by the kidney.
Lead Product(s): Sotagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: SAR439954
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2022
Details:
Both SCORED and SOLOIST-WHF achieved their respective primary endpoints for SAR439954 (sotagliflozin), an investigational oral dual inhibitor of two proteins responsible for glucose regulation (SGLT1 and SGLT2), with overall tolerability similar to placebo across both trials.
Lead Product(s): Sotagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: SAR439954
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: University of Michigan
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2022
Details:
SAR439954 (sotagliflozin) is an investigational oral dual inhibitor of two proteins responsible for glucose regulation known as sodium-glucose co-transporter types 1 and 2.
Lead Product(s): Sotagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: SAR439954
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2022
Details:
Lexicon intends to use the net proceeds funding for continued development, pre-commercial and commercial launch activities for SAR439954 (sotagliflozin) in heart failure and LX9211 in neuropathic pain, and working capital and other general corporate purposes.
Lead Product(s): Sotagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: SAR439954
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Citigroup
Deal Size: $85.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 28, 2022
Details:
Lexicon intends to use the net proceeds funding for continued development, pre-commercial and commercial launch activities for SAR439954 (sotagliflozin) in heart failure and LX9211 in neuropathic pain, and working capital and other general corporate purposes.
Lead Product(s): Sotagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: SAR439954
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Citigroup
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering July 27, 2022
Details:
Discovered using Lexicon’s unique approach to gene science, SAR439954 (sotagliflozin) is an oral dual inhibitor of two proteins responsible for glucose regulation known as sodium-glucose co-transporter types 1 and 2 (SGLT1 and SGLT2).
Lead Product(s): Sotagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: SAR439954
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2022
Details:
Sotagliflozin, an investigational oral dual inhibitor of two proteins responsible for glucose regulation known as sodium-glucose co-transporter types 1 and 2. SGLT1 is responsible for glucose absorption in GIT and SGLT2 is responsible for glucose reabsorption by kidney.
Lead Product(s): Sotagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: SAR439954
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2022
Details:
The analysis evaluated effect of sotagliflozin on MACE in patients with CVD and without CVD at baseline. The analysis showed consistent reductions in MACE in both subgroups with a relative risk reduction in MACE of 21% in patients with and 26% in patients without CVD.
Lead Product(s): Sotagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: SAR439954
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2022
Details:
Sotagliflozin, an investigational oral dual inhibitor of two proteins responsible for glucose regulation known as SGLT1 and SGLT2, is approved in European Union for use as an adjunct to insulin therapy to improve blood sugar control in adults with type 1 diabetes.
Lead Product(s): Sotagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: SAR439954
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2022
Details:
Discovered using Lexicon’s unique approach to gene science, sotagliflozin is an investigational oral dual inhibitor of two proteins responsible for glucose regulation known as sodium-glucose co-transporter types 1 and 2 (SGLT1 and SGLT2).
Lead Product(s): Sotagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: SAR439954
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Oxford Finance
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing March 17, 2022
Details:
The submission is supported by the results of sotagliflozin from the SOLOIST study in patients with type 2 diabetes who had recently hospitalized for heart failure and the SCORED study in patients with type 2 diabetes, chronic kidney disease and for cardiovascular disease.
Lead Product(s): Sotagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: SAR439954
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 30, 2021
Details:
In the new analysis of pooled clinical data from the SOLOIST and SCORED trials, sotagliflozin consistently reduced total cardiovascular deaths, hospitalizations for heart failure, and urgent visits for heart failure across the full range of kidney function.
Lead Product(s): Sotagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: SAR439954
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2021
Details:
The primary endpoint was the total number of events comprised of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure in patients treated with sotagliflozin compared with placebo.
Lead Product(s): Sotagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: SAR439954
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2021
Details:
Sotagliflozin is a first-in-class, investigational dual SGLT1 and SGLT2 inhibitor that showed substantial reductions vs placebo, in the primary endpoint of total cardiovascular deaths, hospitalizations for heart failure, and urgent visits for heart failure in both studies.
Lead Product(s): Sotagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: SAR439954
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2021
Details:
Results from two clinical trials show significant and early benefits from sotagliflozin, a drug that inhibits sodium-glucose transport protein 2 and sodium-glucose transport protein 1 in reducing heart failure, heart attack, and stroke—major problems in people with diabetes.
Lead Product(s): Sotagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: SAR439954
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2021
Details:
The feedback was provided in response to a request made by Lexicon following the completion of the SOLOIST and SCORED studies relating to the potential submission of an NDA based on the results of such studies.
Lead Product(s): Sotagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: SAR439954
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 14, 2021
Details:
Sotagliflozin significantly reduced total cardiovascular deaths, heart failure hospitalization and urgent visits, achieving primary endpoint in both studies.
Lead Product(s): Sotagliflozin
Therapeutic Area: Endocrinology Product Name: Zynquista
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2020
Details:
The observed safety profile of sotagliflozin in these studies was generally consistent with that of approved SGLT2 inhibitors.
Lead Product(s): Sotagliflozin
Therapeutic Area: Endocrinology Product Name: Zynquista
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
